DecisionMap Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$535K Buy
11,151
+1,330
+14% +$57.1K 0.3% 74
2026
Q1
$361K Sell
9,821
-1,531
-13% -$72.5K 0.23% 90
2025
Q4
$578K Buy
11,352
+670
+6% +$34.3K 0.36% 73
2025
Q3
$593K Buy
10,682
+2,264
+27% +$133K 0.38% 70
2025
Q2
$581K Buy
8,418
+1,052
+14% +$71.6K 0.4% 68
2025
Q1
$512K Buy
7,366
+1,661
+29% +$137K 0.39% 69
2024
Q4
$491K Buy
+5,705
New +$617K 0.39% 70

Other funds holding NVO

DecisionMap Wealth Management's NVO Position: Q2 2026 in Review

DecisionMap Wealth Management increased its Novo Nordisk (NVO) stake by 14% in Q2 2026, buying an estimated $57.1K and bringing the position to 11,151 shares worth $535K. The position accounts for 0.3% of the portfolio, ranked #74.

DecisionMap Wealth Management first reported a position in NVO in Q4 2024 and has held it in 7 quarters since. The position peaked at $593K in Q3 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • DecisionMap Wealth Management held 11,151 shares of Novo Nordisk worth $535K as of Q2 2026.
  • DecisionMap Wealth Management bought 1,330 Novo Nordisk shares in Q2 2026, an estimated $57.1K.
  • Novo Nordisk made up 0.3% of DecisionMap Wealth Management's portfolio in Q2 2026, its #74 holding.
  • DecisionMap Wealth Management first reported a position in Novo Nordisk in Q4 2024 and has held it in 7 quarters since.
  • DecisionMap Wealth Management's Novo Nordisk position peaked at $593K in Q3 2025.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on DecisionMap Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.